placebo controlled clinical trials

Related by string. * placebos . Placebo . Placebos : blind placebo controlled . randomized placebo controlled . double blind placebo / controlling . controller . Controller : randomized controlled trial . obtaining controlled substance . randomized controlled trials / clinicals . CLINICAL : Phase III clinical trials . Phase III clinical / trialed . trialing : Week Premium Trial . Phase III trials * *

Related by context. All words. (Click for frequent words.) 76 placebo controlled trials 76 placebo controlled studies 71 placebo controlled clinical 70 prucalopride 69 dose regimens 68 randomized controlled clinical trials 68 HCV SPRINT 68 dosage regimens 68 RRMS patients 68 APTIVUS r 68 RSD# oral 68 fluvastatin 67 oral rivaroxaban 67 ALT flares 67 relapsed MM 67 dosing cohorts 67 randomized clinical trials 67 PREZISTA r 67 Raptiva ® 67 ARCOXIA 67 diabetic neuropathic pain 67 desvenlafaxine succinate 66 mg doses 66 teriflunomide 66 dosing cohort 66 secondary efficacy endpoints 66 clinical pharmacology studies 66 #mg doses [002] 66 active comparator 66 dose cohorts 66 adalimumab 66 solifenacin 66 mcg doses 66 placebo controlled Phase 66 placebo controlled Phase III 66 GSK# [001] 66 ACTEMRA TM 66 lacosamide 65 CANCIDAS 65 dose cohort 65 JANUVIA 65 trials RCTs 65 events AEs 65 ruboxistaurin 65 multicenter trials 65 mg dose 65 randomized controlled trials 65 Dacogen injection 65 apremilast 65 viral kinetic 65 paliperidone ER 65 posaconazole 65 ritonavir boosted 65 multicenter placebo controlled 65 darunavir ritonavir 65 phase IIb 65 RE LY ® 65 blinded randomized placebo controlled 65 dose escalation phase 65 CIMZIA ™ 65 comparator arm 65 HCV RESPOND 2 65 MERLIN TIMI 65 RCTs 65 rasagiline 65 phase IIb trial 65 riociguat 65 pharmacokinetic studies 64 ATACAND 64 double blinded placebo 64 REMICADE ® 64 bendamustine 64 bosentan 64 refractory CLL 64 HBeAg negative patients 64 fenofibric acid 64 Tarceva TM 64 STELARA 64 REMINYL ® 64 mg kg dose 64 brivaracetam 64 tolerability profiles 64 MIRAPEX 64 CHAMPION PCI 64 INC# 64 GAMMAGARD 64 insulin detemir 64 RLAI 64 CAMMS# 64 ORENCIA ® 64 risperidone Risperdal 64 mcg BID 64 efalizumab 64 randomized controlled trials RCTs 64 prospectively defined 64 randomized trials 64 certolizumab 64 MIRCERA 64 tapentadol ER 64 dose titration 64 mg BID 64 sunitinib malate 64 ponatinib 64 AIR CF1 64 atazanavir ritonavir 64 divalproex sodium 64 Teriflunomide 64 PROMACTA 64 Phase 1b trial 64 abatacept 64 phase IIa 64 events SAEs 64 pioglitazone HCl 64 AGILECT R 64 intermittent dosing 64 vismodegib 64 neuropsychiatric symptoms 63 Ophena TM 63 vandetanib 63 confirmatory clinical 63 BoNTA 63 NATRECOR R 63 Phase IIIb clinical 63 SEROQUEL XR 63 AZILECT R 63 TDF FTC 63 dosing intervals 63 Neupro R 63 olanzapine LAI 63 LEXIVA r 63 milligram doses 63 FAMPYRA 63 primary hypercholesterolemia 63 CIMZIA TM 63 tocilizumab 63 glatiramer acetate 63 DLTs 63 FOLPI 63 low dose cytarabine 63 lipid lowering agents 63 PRADAXA 63 Betaferon ® 63 aripiprazole Abilify 63 NATRECOR ® 63 budesonide foam 63 Navelbine ® 63 thorough QT 63 #mg/day [001] 63 mycophenolate mofetil 63 phase IIb clinical 63 alicaforsen enema 63 FOSRENOL ® 63 zolmitriptan 63 HMG CoA reductase inhibitors 63 Perforomist Inhalation Solution 63 montelukast 63 briakinumab 63 trastuzumab Herceptin ® 63 Phase IIa trials 63 MYCAMINE 63 antihypertensive therapy 63 hour bronchodilation 63 AGILECT ® 63 guanfacine extended release 63 elotuzumab 63 randomized multicenter trial 63 COMFORT II 63 patients evaluable 63 ZOLINZA 63 mcg dose 63 analgesic efficacy 63 ABC/3TC 63 MAGE A3 ASCI 63 #mg dose [001] 63 phase Ib 63 #mg dose [002] 63 RAPTIVA 63 alvespimycin 63 tegaserod 63 bicifadine 63 tipranavir 63 DAPT 63 BRIM3 63 weekly subcutaneous injections 63 blinded placebo controlled 63 VFEND 63 pitavastatin 63 meta analyzes 63 subgroup analyzes 63 Phase III trials 63 MoxDuo IR 63 goserelin 62 decitabine 62 RoACTEMRA 62 APTIVUS 62 oral ridaforolimus 62 heavily pretreated 62 INVEGA ® 62 β blockers 62 headache nasopharyngitis 62 TYGACIL 62 placebo controlled randomized 62 budesonide pMDI 62 protease inhibitor PI 62 paliperidone palmitate 62 Jevtana 62 ibandronate 62 subcutaneously administered 62 pramipexole 62 intravenous bisphosphonates 62 multicenter Phase III 62 efficacy endpoint 62 indiplon capsules 62 timepoints 62 abiraterone acetate 62 rFVIIa 62 genotypic resistance 62 SCIg 62 dose proportionality 62 teduglutide 62 VIRAMUNE XR 62 oral FTY# 62 antiepileptics 62 flutamide 62 severe hypercholesterolemia 62 crizotinib PF # 62 BARACLUDE ® 62 TEAEs 62 Peg IFN 62 8mg/kg 62 tolvaptan 62 anakinra 62 guanfacine 62 COPAXONE R 62 mg administered orally 62 placebo controlled 62 PREZISTA rtv 62 unresectable HCC 62 HBeAg positive patients 62 GOUT 62 methotrexate monotherapy 62 interferon alfa 2b 62 virological response 62 salmeterol fluticasone 62 Phase III placebo controlled 62 maximally tolerated dose 62 eltrombopag 62 Arranon 62 arzoxifene 62 peginterferon alfa 2b 62 prior chemotherapy regimens 62 Phase Ib clinical 62 interferon gamma 1b 62 evaluable subjects 62 KAPIDEX 62 ADAGIO study 62 vicriviroc 62 EURIDIS 62 mcg albinterferon alfa 2b 62 #mg dose [003] 62 efficacy endpoints 62 oral diclofenac 62 galiximab 62 lasofoxifene 62 Phase 2a trial 62 APTIVUS ritonavir 62 Torisel 62 Phase IIIb study 62 mg QD 62 ANCHOR trial 62 levetiracetam 62 MGd 62 ACZ# 62 zafirlukast 62 CYPHER R Sirolimus eluting 62 AVERROES 62 randomized blinded 62 biologic DMARD 62 antiretroviral naive 62 SNT MC# 62 REYATAZ R 62 mg Pycnogenol 62 symptomatic BPH 62 ROTATEQ 62 TYKERB 62 Focalin XR 62 HAART regimens 62 ORENCIA R 62 canakinumab 62 randomized clinical 62 Pemetrexed 62 mg RDEA# 62 TNF alpha inhibitor 62 LIALDA 62 oxcarbazepine 62 heavily pretreated patients 62 cholinesterase inhibitor 62 ACTEMRA 62 baminercept 62 FAME Study 62 Allovectin 7 ® 62 Plicera 62 Zavesca R 62 recurrent glioblastoma multiforme 62 EVIZON 62 chlorambucil 62 eosinophilic asthma 62 MabCampath 62 ULORIC 62 neratinib 62 Paxil paroxetine 62 immunomodulatory therapy 62 dosing regimens 62 paricalcitol 61 ramelteon 61 rALLy trial 61 VaD 61 paroxetine Seroxat 61 clevidipine 61 eculizumab therapy 61 ruxolitinib 61 metastatic RCC 61 fluoxetine paroxetine 61 alemtuzumab treated 61 prospective observational 61 randomized #:#:# 61 insulin degludec 61 YONDELIS 61 ascending doses 61 forodesine 61 evaluating REVLIMID 61 Raptiva R 61 axitinib 61 mesalamine granules 61 lenalidomide dexamethasone 61 linagliptin 61 INCB# [003] 61 Tracleer R 61 Rebif ® 61 lanthanum carbonate 61 treatment naive genotype 61 gadobutrol 61 multicenter Phase 61 Traficet EN 61 BYDUREON 61 ribavirin therapy 61 superficial bladder cancer 61 mGluR5 NAM 61 etanercept 61 saquinavir ritonavir 61 Lu AA# 61 reboxetine 61 CALGB 61 Proellex TM 61 Doxil ® 61 ZACTIMA 61 alvimopan 61 adalimumab Humira 61 oxymorphone ER 61 PRECiSE 61 ancrod 61 EDEMA3 61 BARI 2D 61 visilizumab 61 hypogonadal men 61 gemifloxacin 61 Byetta exenatide 61 Fludara 61 lenalidomide Revlimid R 61 CTAP# Capsules 61 SPIRIVA HandiHaler 61 haloperidol Haldol 61 oral antidiabetic agents 61 REVLIMID ® 61 phase IIb study 61 topical NSAIDs 61 Xelox 61 nadolol 61 citalopram 61 azacitidine 61 nab paclitaxel 61 intravenous dosing 61 dose dose escalation 61 ZYVOX 61 ONTARGET 61 EXJADE 61 INTELENCE 61 telaprevir dosing 61 tenofovir emtricitabine 61 iniparib 61 Phase IIb trial 61 severe hypersensitivity reactions 61 PRIMO CABG 61 LEUKINE 61 Serious adverse reactions 61 FOLFIRINOX 61 receptor tyrosine kinase inhibitor 61 PEGINTRON TM 61 evaluating mipomersen 61 mg/m2 dose 61 dapagliflozin plus 61 Abilify aripiprazole 61 dirucotide MBP# 61 SUTENT 61 virological failure 61 pharmacokinetic parameters 61 GnRH agonists 61 DEB# 61 etravirine 61 safinamide 61 boosted protease inhibitor 61 pyridostigmine 61 pomalidomide 61 Vimpat R 61 anthracyclines taxanes 61 zileuton 61 tolterodine ER 61 dietary questionnaires 61 TMC# r 61 EDARBI 61 mg eq 61 REVLIMID lenalidomide 61 LPV r 61 NOXAFIL 61 clobazam 61 randomized placebo controlled 61 phase IIIb 61 AZILECT 61 efavirenz EFV 61 maximal doses 61 antimuscarinic 61 double blinded randomized 61 OvaRex MAb 61 Onrigin 61 clinically meaningful improvements 61 DDP# 61 NUVIGIL 61 bazedoxifene 61 REYATAZ r arm 61 Cimzia ® 61 tolerability profile 61 ExTRACT TIMI 61 RESIST studies 61 pegaptanib 61 cladribine tablets 61 landmark ATHENA 61 Engerix B 61 acitretin 61 Phase 2b study 61 GFT# 61 Tolvaptan 61 MAS XR 61 DMARDS 61 ARIXTRA 61 doxorubicin cyclophosphamide 61 achieved statistical significance 61 TNF inhibitor 61 atazanavir sulfate 61 antiepileptic drugs AEDs 61 ritonavir boosted atazanavir 61 LEVAQUIN ® 61 TNF antagonist 61 Afatinib 61 dose limiting toxicities 61 phase III isavuconazole 61 ketoconazole 61 docetaxel chemotherapy 61 darunavir 61 melphalan prednisone 61 methylnaltrexone 61 achieved ACR# 61 CIMZIA TM certolizumab pegol 61 Cipralex ® 61 KRAS status 60 THALOMID 60 CAELYX 60 INSPIRE Trial Phase III 60 coinfected patients 60 romiplostim 60 aleglitazar 60 DMARD therapy 60 Phase IIB 60 ONGLYZA saxagliptin 60 Wisconsin Sleep Cohort 60 Soriatane 60 ziprasidone Geodon 60 aldosterone antagonists 60 VPRIV 60 cilostazol 60 receiving INTRON 60 peginterferon alfa 2a 60 ximelagatran 60 PegIntron 60 Mylotarg 60 febuxostat 60 Primary endpoints 60 TELCYTA 60 SEROQUEL 60 AZOR 60 Zemplar Capsules 60 selegiline 60 venlafaxine ER 60 Seliciclib 60 virologic failure 60 diuretic chlorthalidone 60 Phase IIa trial 60 DASISION 60 Epivir HBV 60 venlafaxine Effexor 60 lumiracoxib 60 tipranavir ritonavir 60 tacrolimus ointment 60 MACUGEN 60 TORISEL 60 Dose escalation 60 venlafaxine 60 sertraline Zoloft 60 ONGLYZA 60 QNEXA 60 4CMenB 60 olmesartan 60 oxaliplatin Eloxatin 60 IFN beta 60 retrospective cohort 60 candesartan cilexetil 60 balsalazide tablet 60 6R BH4 60 Study GL# 60 somatostatin analog 60 AZT zidovudine Retrovir 60 Vandetanib 60 LibiGel Phase III 60 mirtazapine 60 phase IIa clinical 60 titrated glipizide 60 microgram doses 60 Keppra R 60 EMPHASIS HF trial 60 MIRAPEX ER 60 ALGRX 60 discontinuations due 60 NeuroStar TMS Therapy 60 LATUDA 60 lixisenatide 60 weekly intravenous infusions 60 LY# [003] 60 ISENTRESS 60 metastatic HRPC 60 subcutaneous PRO 60 dopamine partial agonist 60 ALVESCO HFA 60 Pegasys ® 60 metreleptin 60 null responder HCV 60 ascending dose 60 entecavir 60 Aptivus ® 60 triamcinolone 60 systemic ALCL 60 FOLFIRI 60 FROVA 60 multicenter multinational 60 AVOREN 60 FOSRENOL R 60 Phase III Clinical Trials 60 favorable pharmacokinetic profile 60 vildagliptin 60 postmenopausal osteoporotic women 60 aplindore 60 latrepirdine 60 Increlex R 60 basal bolus regimen 60 epoetin alfa 60 liver transplant recipients 60 insulin glulisine 60 pamidronate 60 oxycodone CR 60 HBeAg positive 60 relapsing remitting MS RRMS 60 pharmacokinetics PK 60 tasocitinib 60 INFERGEN 60 clomipramine 60 Tekamlo 60 glargine 60 ezogabine 60 randomized Phase III 60 Pivotal Phase III 60 ganetespib 60 R# #mg BID 60 subcutaneous dose 60 virologic breakthrough 60 bupropion SR 60 mixed dyslipidemia 60 vidofludimus 60 rufinamide 60 enfuvirtide 60 Flu Cy 60 amoxicillin clavulanate 60 raltegravir 60 aldosterone antagonist 60 SYMMETRY trial 60 Meta analyzes 60 VADT 60 dasatinib 60 Phase Ib 60 dose escalation Phase 60 zonisamide 60 daily subcutaneous injections 60 TNF inhibitors 60 ritonavir boosted lopinavir 60 FOLPI regimen 60 CYPHER Stent 60 sorafenib Nexavar 60 urocortin 2 60 methotrexate therapy 60 mitoxantrone 60 Bronchitol 60 FRAGMIN 60 PRADAXA #mg 60 treatment emergent AEs 60 venlafaxine XR 60 Pharmacokinetic parameters 60 AZILECT ® 60 selective modulator 60 Octreolin 60 Aryplase 60 eszopiclone 60 RISPERDAL ® 60 CONCERTA 60 #mg QD [001] 60 splenectomized patients 60 tolevamer 60 glatiramer 60 Board DSMB 60 viral kinetics 60 SinuNase TM 60 steroid dexamethasone 60 ziprasidone 60 Subgroup analyzes 60 INCB# [001] 60 AIR CF2 60 renal toxicity 60 S/GSK# 60 Cloretazine 60 androgen suppression 60 trastuzumab emtansine T DM1 60 BOLDER II 60 timepoint 60 Vidaza azacitidine 60 Triolex 60 inhaled anticholinergics 60 Pafuramidine 60 Phase IIIb 60 prospective observational studies 60 mCRC patients 60 CLARITY study 60 adjunctive placebo 60 plasma pharmacokinetics 60 Bezielle 60 albinterferon alfa 2b 60 peg IFN 60 plus methotrexate 60 ECASS 60 ToGA 60 fluoxetine Prozac 60 EFFEXOR XR 60 valacyclovir 60 antiretroviral naïve 60 bolus dose 60 tigecycline 60 peginterferon alfa 60 serotonin norepinephrine reuptake inhibitor 60 estramustine 60 docetaxel Taxotere ® 60 EFAPROXYN 60 nonclinical studies 60 Zolinza 60 edoxaban 60 Vectibix monotherapy 60 Mg Uk 60 Zytiga 60 ACCORD Lipid 60 GetGoal Phase III 60 rosuvastatin calcium 60 investigational protease inhibitor 60 Aptivus 60 Raptiva r 60 relapsed SCLC 60 pegylated interferon alfa 60 KRAS mutations occur 60 rilonacept 60 tolterodine 60 achieved PASI 60 undetectable HBV DNA 60 remission CR 60 enalapril 60 temsirolimus 60 myopathy rhabdomyolysis 60 antitumor effects 60 Serious Adverse Events 60 Gabapentin GR 60 MoxDuo TM IR 60 colesevelam HCl 60 doripenem 60 ONTAK 60 HIV HCV coinfected 60 rizatriptan 60 nilotinib 60 haematologic 60 Welchol 59 paclitaxel eluting stents 59 fostamatinib 59 Phase IIb trials 59 opioid naïve 59 anthracycline taxane 59 anti leukemic 59 dexpramipexole 59 anagrelide 59 coadministration 59 bosutinib 59 telcagepant 59 valopicitabine 59 ziconotide 59 Toviaz 59 pharmacokinetic interactions 59 pharmacokinetic characteristics 59 bicalutamide 59 bardoxolone methyl 59 Navelbine 59 retapamulin 59 demonstrated antitumor activity 59 atazanavir 59 blind randomized placebo 59 desvenlafaxine 59 FOLFOX4 59 clinical trial 59 BR.# 59 Tekturna HCT 59 aclidinium 59 monotherapy 59 Nexavar sorafenib 59 lipid lowering therapy 59 4mg/kg 59 enzastaurin 59 quetiapine fumarate 59 lopinavir r arm 59 fosbretabulin 59 lubiprostone 59 #mg/m# [002] 59 evaluable patients 59 oral antidiabetes drugs 59 deferiprone 59 rosuvastatin Crestor 59 sitagliptin 59 Taxotere ® 59 #I TM# 59 octreotide 59 LEXIVA 59 Zavesca ® 59 OvaRex ® MAb 59 pharmacodynamics 59 BARACLUDE R 59 Epoetin alfa 59 EOquin TM phase 59 Phase Ib study 59 novel VDA molecule 59 urate lowering 59 ustekinumab 59 PROactive study 59 rilpivirine 59 midstage clinical 59 pramlintide 59 HORIZONS AMI trial 59 ALLHAT 59 ataluren 59 LT NS# 59 relapsed refractory multiple myeloma 59 clazosentan 59 inhalations twice 59 3TC lamivudine Epivir 59 leflunomide 59 UPLYSO 59 multicenter randomized placebo controlled 59 pharmacodynamic effects 59 oral prednisone 59 quetiapine XR 59 Protelos 59 oral iron chelator 59 PEARL SC 59 GLYX 59 AVANDIA 59 odanacatib 59 idraparinux 59 acute HAE attacks 59 Proleukin 59 quetiapine 59 plasma kallikrein inhibitor 59 APRISO 59 Onbrez Breezhaler 59 Phase III randomized controlled 59 Eliquis 59 treatment naïve genotype 59 teriparatide 59 motesanib 59 golimumab CNTO 59 Cochrane reviewers 59 antidepressant efficacy 59 NEVO ™ 59 ARIMIDEX 59 irbesartan 59 PRT# 59 VIIBRYD 59 lesinurad 59 Sutent sunitinib 59 intravitreal injection 59 paroxetine Paxil 59 leukotriene receptor antagonists 59 Requip XL 59 ocrelizumab 59 Celsentri Selzentry 59 Hepatotoxicity 59 TNF antagonists 59 Phase 1b clinical 59 Phenoptin 59 peginterferon alfa 2a Pegasys 59 Phase 1a clinical 59 caspofungin 59 octreotide LAR 59 parecoxib 59 NSABP B 59 darunavir r 59 cannabinor 59 LCP Tacro ™ 59 TREDAPTIVE 59 randomized Phase IIb 59 partial remissions 59 Cancidas 59 tiotropium 59 COPAXONE ® 59 dyskinesia PD LID 59 hypercalcemia 59 palifermin 59 sorafenib tablets 59 clinical trials 59 ADVANCE PD 59 PASI scores 59 Candesartan 59 preclinical efficacy 59 Aflibercept 59 1mg dose 59 ASCEND HF 59 pramlintide metreleptin combination 59 rindopepimut 59 ROCKET AF 59 TRILIPIX 59 blind placebo 59 Amrubicin 59 prospective randomized placebo 59 Eltrombopag 59 VELCADE melphalan 59 heFH 59 REYATAZ ritonavir 59 TELINTRA 59 GRALISE 59 μg dose 59 CDP# 59 acromegalic patients 59 EOquin TM 59 sitaxsentan 59 midstage trials 59 INVEGA ® SUSTENNA ® 59 metformin sulfonylurea 59 Celebrex celecoxib 59 lumiliximab 59 selective phosphodiesterase 59 CLL8 59 MEVACOR 59 nitazoxanide 59 antidepressants fluoxetine 59 phase 2a 59 Hycamtin 59 mapatumumab 59 Cimzia TM 59 refractory multiple myeloma 59 composite endpoint 59 Pegasys plus Copegus 59 Keppra ® 59 denufosol 59 noninferiority 59 HuMax CD# 59 IBS C 59 PROSTVAC ® 59 PEGylated interferon beta 1a 59 DPNP 59 subcutaneous doses 59 romidepsin 59 NVA# 59 ARCALYST ® 59 abacavir lamivudine 59 hyperphenylalaninemia HPA due 59 efficacy tolerability 59 pimecrolimus 59 Femara letrozole 59 SSRI SNRI 59 postmarketing 59 nitrofurantoin 59 Chronic Idiopathic Constipation 59 Pimavanserin 59 Triapine R 59 Golimumab 59 dose escalation 59 1mg 2mg 59 hepatitis C genotype 59 #mg ATC 59 TRISENOX 59 eribulin mesylate 59 metformin HCl 59 anastrazole 59 newer antipsychotic medications 59 clinically meaningful differences 59 injectable formulations 59 nucleotide analogue 59 ixabepilone 59 randomized multicenter Phase III 59 ZYBRESTAT fosbretabulin 59 Advagraf 59 alfa 2a 59 Nasacort AQ 59 citalopram hydrobromide 59 pregabalin 59 antihypertensive medications 59 HBV infections 59 subanalysis 59 Hyphanox 59 Veramyst 59 Perforomist TM Inhalation Solution 59 Avanafil 59 RezularTM 59 miconazole 59 pegylated interferon alfa 2b 59 TAXUS VI 59 Velcade bortezomib 59 dacarbazine chemotherapy 59 SAR# [004] 59 XGEVA 59 nonrandomized 59 lopinavir ritonavir 59 mitoxantrone plus 59 Phase 2b trial 59 Phase III clinical trials 59 Cariprazine 59 PegIFN RBV 59 RhuDex 59 NPH insulin 59 prospective observational cohort 59 strontium ranelate 59 #mg BID [001] 59 peg interferon 59 avosentan 59 relapsed MCL 59 PROSTVAC TM 59 pharmacodynamics PD 59 DU #b 59 non squamous NSCLC 59 Dasatinib 59 angiographic outcomes 59 aripiprazole 59 evaluable 59 placebo dexamethasone 59 randomized controlled clinical 59 rotigotine 59 Phase IIa clinical trials 59 pharmacokinetic profiles 59 rheumatoid arthritis HUMIRA 59 randomized Phase 2b 59 dosing schedules 59 casopitant 59 DMARD 59 Committee IDMC 58 5-FU/LV 58 Tesmilifene 58 SAEs 58 tibolone 58 Sprycel dasatinib 58 YERVOY 58 pegylated interferon alfa 2a 58 rheumatoid arthritis psoriatic arthritis 58 Entereg R 58 FTY# 58 CLARITY TIMI 58 MADIT CRT trial 58 sunitinib Sutent 58 imipramine 58 EDEMA3 trial 58 plus COPEGUS 58 Randomized Phase 58 Viread Emtriva 58 Roche Xeloda

Back to home page